Literature DB >> 28456940

MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Eduard R Mingazov1, Gulnara R Khakimova1, Elena A Kozina1, Alexei E Medvedev2, Olga A Buneeva2, Ara S Bazyan3, Michael V Ugrumov4,5.   

Abstract

Parkinson's disease (PD) is characterized by the appearance of motor symptoms many years after the onset of neurodegeneration, which explains low efficiency of therapy. Therefore, one of the priorities in neurology is to develop an early diagnosis and preventive treatment of PD, based on knowledge of molecular mechanisms of neurodegeneration and neuroplasticity in the nigrostriatal system. However, due to inability to diagnose PD at preclinical stage, research and development must be performed in animal models by comparing the nigrostriatal system in the models of asymptomatic and early symptomatic stages of PD. In this study, we showed that despite the progressive loss of neurons in the substantia nigra at the presymptomatic and symptomatic stage, almost no change was observed in the main functional characteristics of this brain region, including dopamine (DA) uptake and release, dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) expression, and activity of MAO-A and MAO-B. In the striatum of presymptomatic mice, some parameters (DA release and uptake, MAO-A activity) remained compensatory unchanged or compensatory decreased (MAO-B gene expression and activity), while others-a reduction in DA levels in tissue and extracellular space and in VMAT2 and DAT expression-manifest the functional failure. In symptomatic mice, only a few parameters (spontaneous DA release and uptake, MAO-B gene expression and activity) remained at the same level as at presymptomatic stage, while most parameters (DA level in tissue and extracellular space, DA-stimulated release, VMAT2 and DAT contents), decreased, showing decompensation, which was enhanced by increasing MAO-A activity. Thus, this study provides a comprehensive assessment of the molecular mechanisms of neuroplasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine models of preclinical and clinical stages of PD, which could potentially serve as a powerful tool for translational medicine.

Entities:  

Keywords:  Dopaminergic neurons; MPTP; Mice; Nigrostriatal system; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28456940     DOI: 10.1007/s12035-017-0559-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  72 in total

Review 1.  Looking backward to move forward: early detection of neurodegenerative disorders.

Authors:  Steven T DeKosky; Kenneth Marek
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

Review 3.  The Parkinson's complex: parkinsonism is just the tip of the iceberg.

Authors:  J William Langston
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

4.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

5.  Effect of the dopaminergic neurotoxin MPTP on cocaine-induced locomotor sensitization.

Authors:  Y Itzhak; J L Martin; M D Black; S F Ali
Journal:  Pharmacol Biochem Behav       Date:  1999-05       Impact factor: 3.533

6.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

7.  Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.

Authors:  T Chaumette; T Lebouvier; P Aubert; B Lardeux; C Qin; Q Li; D Accary; E Bézard; S Bruley des Varannes; P Derkinderen; M Neunlist
Journal:  Neurogastroenterol Motil       Date:  2008-12-05       Impact factor: 3.598

8.  In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.

Authors:  Nobuyuki Okamura; Victor L Villemagne; John Drago; Svetlana Pejoska; Rajinder K Dhamija; Rachel S Mulligan; Julia R Ellis; Uwe Ackermann; Graeme O'Keefe; Gareth Jones; Hank F Kung; Michael J Pontecorvo; Daniel Skovronsky; Christopher C Rowe
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

Review 9.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

10.  Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases.

Authors:  David S Goldstein; LaToya Sewell
Journal:  Parkinsonism Relat Disord       Date:  2009-02-07       Impact factor: 4.891

View more
  7 in total

1.  Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology.

Authors:  Madelyn C Houser; W Michael Caudle; Jianjun Chang; George T Kannarkat; Yuan Yang; Sean D Kelly; Danielle Oliver; Valerie Joers; Kathleen M Shannon; Ali Keshavarzian; Malú Gámez Tansey
Journal:  Acta Neuropathol Commun       Date:  2021-08-19       Impact factor: 7.801

Review 2.  Parkinson's Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes.

Authors:  Madalina-Andreea Robea; Ioana-Miruna Balmus; Alin Ciobica; Stefan Strungaru; Gabriel Plavan; Lucian Dragos Gorgan; Alexandra Savuca; Mircea Nicoara
Journal:  Oxid Med Cell Longev       Date:  2020-08-18       Impact factor: 6.543

3.  Effects of Brain Factor‑7® against motor deficit and oxidative stress in a mouse model of MPTP‑induced Parkinson's disease.

Authors:  Tae-Kyeong Lee; Jae-Chul Lee; Dae Won Kim; Ji-Won Lee; Sung-Su Kim; Hyung-Il Kim; Myoung Cheol Shin; Jun Hwi Cho; Moo-Ho Won; Soo Young Choi
Journal:  Exp Ther Med       Date:  2022-08-24       Impact factor: 2.751

4.  Changes in Tyrosine Hydroxylase Activity and Dopamine Synthesis in the Nigrostriatal System of Mice in an Acute Model of Parkinson's Disease as a Manifestation of Neurodegeneration and Neuroplasticity.

Authors:  Anna Kolacheva; Leyla Alekperova; Ekaterina Pavlova; Alyona Bannikova; Michael V Ugrumov
Journal:  Brain Sci       Date:  2022-06-14

Review 5.  MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies.

Authors:  Musa Mustapha; Che Norma Mat Taib
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

Review 6.  Development of early diagnosis of Parkinson's disease: Illusion or reality?

Authors:  Michael Ugrumov
Journal:  CNS Neurosci Ther       Date:  2020-06-29       Impact factor: 7.035

7.  The Sphingolipid Asset Is Altered in the Nigrostriatal System of Mice Models of Parkinson's Disease.

Authors:  Victor Blokhin; Maria Shupik; Ulyana Gutner; Ekaterina Pavlova; Albert T Lebedev; Olga Maloshitskaya; Vsevolod Bogdanov; Sergey Sokolov; Alice Alessenko; Michael Ugrumov
Journal:  Biomolecules       Date:  2022-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.